Subject: Retatrutide Is Too Good… And That’s The Problem
From: Dave Knapp from On The Pen <[email-masked]>
To: [email-masked]
Date: Wed, 25 Mar 2026 01:24:24 +0000
List-Id: <onthepen.substack.com>

View this post on the web at https://onthepen.substack.com/p/retatrutide-is-too-good-and-thats

There’s a lot shifting right now in the world of GLP-1s, and if you rely on compounded or research-grade options, this week’s updates may feel especially important.
From new signals out of Washington that could impact access, to powerful new data on next-generation treatments like retatrutide, to where drug companies are heading next…things are moving quickly on multiple fronts.
We break it all down in this week’s episode, what’s changing, what it could mean for you, and what to keep an eye on next.
The Throttling of Compounded GLP-1sFDA vs Telehealth, What’s Really HappeningThe Truth About “Research Peptides”The Rule That Created the Black Market If You Rely on This, Here’s What’s ComingWhy They Want You Back on Branded DrugsRetatrutide Might Be the Most Powerful YetThe Data That Changes Everything (Diabetes + Weight Loss)What Comes After GLP-1s, The Next Wave

Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9vbnRoZXBlbi5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNakF4TnpBME55d2lhV0YwSWpveE56YzBOREF4T0RjMExDSmxlSEFpT2pFNE1EVTVNemM0TnpRc0ltbHpjeUk2SW5CMVlpMDBPREE0T1Rreklpd2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Ll8xanA0cE5ZNmFzTWwwQjlmcDBqNmpVSFJ6bkZaSGg4MXowS3d3Q095YTQiLCJwIjoxOTIwMTcwNDcsInMiOjQ4MDg5OTMsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc0NDAxODc0LCJleHAiOjIwODk5Nzc4NzQsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.KpXKIDwpVfDhoHk-gAjcd2OLqj7CoUCJXzUcu4mcHJ4?